Microport Cardioflow Medtech

Microport Cardioflow Medtech Current Liabilities

The Current Liabilities of Microport Cardioflow Medtech (2160.HK) as of Nov 15, 2026 is 433.89 M CNY. In the previous year, Current Liabilities was 346.45 M CNY — a change of 25.24% (higher).

Current Liabilities

433.89 MCNY

YoY

25.24%

Last updated:

Current Liabilities of Microport Cardioflow Medtech is 2024 433.89 M CNY. Current Liabilities of Microport Cardioflow Medtech was 2023 346.45 M CNY. It decreases by 25.24% higher compared to the previous year.

The Microport Cardioflow Medtech Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
115.21 M CNY
Jan 1, 2019
387.74 M CNY
Jan 1, 2020
1.43 B CNY
Jan 1, 2021
216.17 M CNY
Jan 1, 2022
216.72 M CNY
Jan 1, 2023
346.45 M CNY
Jan 1, 2024
433.89 M CNY
The Microport Cardioflow Medtech Current Liabilities history
YEARCurrent LiabilitiesYoY
433.89 MCNY+25.24%
346.45 MCNY+59.86%
216.72 MCNY+0.25%
216.17 MCNY-84.90%
1.43 BCNY+269.24%
387.74 MCNY+236.55%
115.21 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Microport Cardioflow Medtech Stock analysis

What does Microport Cardioflow Medtech do? MicroPort CardioFlow Medtech Corp. develops and commercializes transcatheter and surgical solutions for valvular heart diseases, primarily focusing on the domestic market. The company's main products are the first-generation TAVI product VitaFlow and the second-generation TAVI product VitaFlow II, which are used for transcatheter aortic heart valve implantation. These products are sold to healthcare providers and hospitals within China, where the company operates under its holding company structure. The firm generates revenue through the sale of its medical devices, specifically the VitaFlow and VitaFlow II systems, targeting hospitals and medical institutions that require advanced cardiac solutions. As a domestic-focused entity, MicroPort CardioFlow's business model relies on the commercialization of its TAVI products within China's healthcare sector, with no mention of international markets or additional product lines beyond the two TAVI systems. Microport Cardioflow Medtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Microport Cardioflow Medtech stock

Current Liabilities of Microport Cardioflow Medtech is 433.89 M CNY in 2024.

Current Liabilities of Microport Cardioflow Medtech changed from 346.45 M CNY to 433.89 M CNY, representing a 25.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Microport Cardioflow Medtech since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Microport Cardioflow Medtech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Microport Cardioflow Medtech

All Key Metrics — Microport Cardioflow Medtech